title: Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016.
abstract: Bioresorbable scaffolds represent an exciting milestone in the development of coronary stent technology with the potential to substantially improve the management of patients with coronary artery disease. In an attempt to provide first recommendations for the technology, experienced experts involved in the first-in-man studies met in Zurich on the 14 April 2016 in order to reach consensus on a responsible market introduction. This document will be updated regularly as new information from clinical trials becomes available and should be understood as a review of current data, opportunities, expectations, advice, and recommendations for future investigations.
authors.affiliation: Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Fajadet
authors.forename: Michael
authors.initials: M
authors.lastname: Haude
authors.forename: Michael
authors.initials: M
authors.lastname: Joner
authors.forename: Jacques
authors.initials: J
authors.lastname: Koolen
authors.forename: Michael
authors.initials: M
authors.lastname: Lee
authors.forename: Ralph
authors.initials: R
authors.lastname: Tölg
authors.forename: Ron
authors.initials: R
authors.lastname: Waksman
mesh_terms: D020341:Absorbable Implants; D001807:Blood Vessel Prosthesis; D018795:Device Approval; D006801:Humans; D018579:Patient Selection; D054457:Tissue Scaffolds